General News

Kalohexis’ lead programs include 710GO, an oral dual melanocortin-3 and-4 receptor (MC3R/MC4R) agonist, a next-generation general obesity treatment; and mifomelatide, a dual MC3R/MC4R antagonist to prevent and treat cachexia in advanced cancers 710GO has shown healthier, more durable weight loss without lean body mass loss and other side effects common with GLP-1 receptor agonists Northbrook,…

NORTHBROOK, Ill., Oct. 2, 2025 /PRNewswire/ — Endevica Bio, a clinical-stage biotechnology company pioneering peptide therapeutics for metabolic diseases, announced a major scientific breakthrough that could redefine the therapeutic landscape for general obesity treatment. The company’s research demonstrates that co-agonism of the melanocortin-3 and melanocortin-4 receptors (MC3/4R) drives robust weight loss, unlocking the melanocortin system as a differentiated mechanism…

NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ — Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first patient in a Phase 2 trial for its experimental drug TCMCB07 (B07) to prevent weight loss in cancer patients undergoing chemotherapy. The trial, being conducted in partnership with WuXi Clinical, will…

The U.S. obesity epidemic is possibly the largest public health scourge our country has ever faced. So far, good news in the progress against this problem has been in short supply.  Weight loss drugs may be changing that.  In a society that has been at war with weight for decades, never have we seen drugs…

As GLP-1s have grown in popularity, there’s been an increasing amount of research into the drugs – sometimes highlighting potentially beneficial side effects but other times spotlighting troubling complications. A recent study in Physiology & Behavior falls into the latter category. Researchers concluded that GLP-1s – used for weight loss and to treat diabetes and…

Cancer patients often experience weight loss associated with cachexia, which can significantly impact the effectiveness of cancer treatments. That includes treatments such as immunotherapy and CAR T-cell therapy. A recent study showed that preventing weight loss can make treatments more effective. The study, published in the journal Blood Advances, found that cancer patients who lost…

The heart muscle faces a silent threat in patients with cancer and other chronic diseases: a life-threatening condition called cachexia. This debilitating syndrome, characterized by severe weight loss and muscle wasting, can extend its insidious reach beyond skeletal muscles, significantly impacting the very fabric of the heart. As cachexia progresses in some patients, the muscles…

The recent market reaction to the trial results of Novo Nordisk’s next-generation weight loss drug highlights a dangerous trend: the overemphasis on losing a significant number of pounds as the sole measure of success. Company executives earlier had predicted on investor calls that the medication, CagriSema could result in weight loss of at least 25%….

We’ve written about the significant toll cachexia can take on adults. But the life-threatening syndrome, characterized by the progressive loss of muscle mass and fat, can have a far more pronounced impact on children. Cachexia, often called “failure to thrive” in children, is associated with chronic illnesses such as cancer. But even if the underlying…

Cachexia is a devastating condition for those suffering from it and for their caregivers. But it’s also taking a toll on Medicare. Cachexia – a syndrome characterized by weight loss that affects many people with cancer and other chronic diseases — is tied to increased hospital admissions, longer hospital stays and a greater need for intensive…